Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.68 |
| ▸ | CHUK | O15111 | 2/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521763 | 0.95 | IKBKB (0.76) | IKBKBCHUKMAPK8MAPK10SYK | |
| SCHEMBL3516494 | 0.90 | IKBKB (0.70) | IKBKBCHUKHDAC4HDAC6MAPK8 | |
| SCHEMBL3520614 | 0.85 | IKBKB (0.69) | IKBKBCHUKHDAC4HDAC6MAPK8 | |
| SCHEMBL3519904 | 0.85 | IKBKB (0.58) | IKBKBCHUKMAPK8MAPK10SYK | |
| SCHEMBL3518050 | 0.85 | GSK3A (0.57) | IKBKBCHUKCDK2CDK1CDK4 | |
| SCHEMBL3516413 | 0.83 | IKBKB (0.58) | IKBKBCHUKMAPK8MAPK10SYK | |
| SCHEMBL3521390 | 0.83 | IKBKB (0.58) | IKBKBCHUKMAPK8MAPK10SYK | |
| SCHEMBL3518974 | 0.83 | IKBKB (0.56) | IKBKBCHUKCDK2CDK4SMG1 | |
| SCHEMBL3518431 | 0.81 | IKBKB (1.00) | IKBKBMAPK8MAPK10SYKCDK2 | |
| SCHEMBL3521180 | 0.81 | IKBKB (0.67) | IKBKBCHUKMAPK8MAPK10SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | claimed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | IKBKB 3482/4885CHUK 1792/4885HDAC4 2587/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | IKBKB 3246/4885CHUK 2096/4885HDAC4 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.